14th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV Washington DC, July 19-21 2012

Conference Reports for NATAP


14th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV Washington DC, July 19-21 2012

	Clinically Significant Drug Interaction Between Colchicine and Ritonavir in Healthy Adults - (12/14/12) Incidence of hypertriglyceridemic waist (HTW) phenotype in a randomized prospective trial comparing atazanavir/ritonavir (ATV/r) and lopinavir/ritonavir (LPV/r) each in combination with tenofovir DF/emtricitabine (TDF/FTC) in antiretroviral naive HIV-1 infected subjects, a sub-study of CASTLE - (09/03/12) Renal function improves with long-term telbivudine therapy in patients with chronic hepatitis B Analysis of the Clinical data Base - (08/20/12) Increased Risk of Serious non-AIDS defining Events and Mortality among Immunological Non-Responders to Antiretroviral Therapy - (08/20/12) Estimated Glomerular Filtration Rates (eGFR) through 144 Weeks on Therapy in HIV-infected Subjects Receiving Atazanavir/ Ritonavir and Abacavir/Lamivudine or Simplified to Unboosted Atazanavir/Abacavir/Lamivudine - (07/23/12) Effects on post-prandial lipids and arterial stiffness of atazanavir/ritonavir versus darunavir/ritonavir in HIV-uninfected adults - (07/23/12) Skeletal muscle toxicity associated with raltegravir-based combination anti-retroviral therapy in HIV-infected adults - (07/23/12) The Impact of Raltegravir and Lopinavir/ritonavir on lipid subfractions, vascular and inflammatory markers in HIV Negative Subjects - (07/23/12) SPIRIT Study: Switching boosted PI to Rilpivirine In-combination with Truvada as a Single-Tablet Regimen Week 24 Results - (07/23/12) Predicting Risk of Cancer During HIV Infection: The Role of Inflammatory and Coagulation Biomarkers - (07/23/12)